Malaria drugs aren't the only ones on the shelf that might help coronavirus patients [Los Angeles Times (CA)]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Los Angeles Times
When a pandemic springs up as fast as the one sparked by the novel coronavirus, doctors must rummage around in their medicine cabinets for drugs that are already available and might be repurposed to treat a wholly new disease. Treating patients with mild or moderate COVID-19 is essentially a preventive mission: The principal aim is to stop the disease from progressing to a severe stage that would typically require mechanical ventilation. But it’s hard to slow or disrupt the progress of an infection when you have only begun to see how it unfolds. And it’s inherently difficult to prove that a particular medicine has prevented severe illness or death when neither was never a sure bet in the first place. Given the lack of other good options, doctors are forced to try these medicines anyway. Among the best known are several antiviral medications — remdesivir , lopinavir and ritonavir — that were developed to treat Ebola and AIDS. Sign up for the latest news, best stories and what they mean
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences Announces First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Announces First Quarter 2024 Financial ResultsBusiness Wire
- Built environment thought leaders discuss pathways to circular economy at Tarkett's third annual Circularity Summit [Yahoo! Finance]Yahoo! Finance
- Notable earnings after Thursday's close [Seeking Alpha]Seeking Alpha
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at HSBC Holdings plc from a "reduce" rating to a "hold" rating. They now have a $69.00 price target on the stock.MarketBeat
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- 4/1/24 - Form 144
- GILD's page on the SEC website